UCB SA (OTCMKTS:UCBJY) Sees Significant Increase in Short Interest

UCB SA (OTCMKTS:UCBJY) was the target of a significant growth in short interest during the month of October. As of October 15th, there was short interest totalling 73,100 shares, a growth of 10,342.9% from the September 30th total of 700 shares. Based on an average trading volume of 53,900 shares, the short-interest ratio is currently 1.4 days.

UCB Stock Performance

OTCMKTS UCBJY opened at $96.28 on Friday. The company has a 50-day moving average price of $91.16 and a two-hundred day moving average price of $79.14. UCB has a 52 week low of $34.85 and a 52 week high of $97.60.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.